AbbVie Ends Work on Drug From $5.8 Billion Deal After Failures

(Bloomberg) -- AbbVie Inc. said it would stop all research on its experimental cancer treatment Rova-T, a drug it bought in its $5.8 billion 2016 takeover of Stemcentrx Inc.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.